… and Andrew King, D.V.M, Ph.D., head of renal … license to atrasentan and our merger with Aduro, and has assumed … deal with Alexion and the merger of Tekmira/Oncore. Prior … treatment of primary hyperoxaluria, as well as research programs for other rare …
VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.
